{"id":"W2601739689","doi":"10.1016/j.diabet.2017.01.004","title":"Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial","year":2017,"lang":"en","type":"article","venue":"Diabetes & Metabolism","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; Medicine; Internal medicine; Type 2 diabetes; Placebo; PCSK9; Insulin; Statin; Diabetes mellitus; Endocrinology; Randomized controlled trial; Gastroenterology; Cholesterol; Lipoprotein; LDL receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008677581,0.001546338,0.002583192,0.0003173759,0.0007922231,0.001303309,0.0007759291,0.00197427,0.003437973],"category_scores_gemma":[0.005548281,0.0006874216,0.001424326,0.000506918,0.001582962,0.0009399246,0.0006434424,0.002581642,0.0007705513],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005646796,"about_ca_system_score_gemma":0.001441397,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004422183,"about_ca_topic_score_gemma":0.0009206039,"domain_scores_codex":[0.9959233,0.002946675,0.0002629123,0.0003963166,0.0002591521,0.0002117166],"domain_scores_gemma":[0.9982664,0.0004261538,0.0003818978,0.0002042346,0.0001761479,0.0005452504],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9469439,0.007453406,0.006872223,0.002050352,0.001289785,0.0001396551,0.0001660767,0.0005981707,0.004713865,0.00105368,0.001787076,0.02693174],"study_design_scores_gemma":[0.8992958,0.07934806,0.0105838,0.0002992516,0.001278907,0.0001677334,0.00005770485,0.001150683,0.001050943,0.001131902,0.005589381,0.00004578379],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.8525873,0.02511028,0.005371444,0.006503763,0.001966649,0.0896902,0.00242315,0.0001617596,0.01618553],"genre_scores_gemma":[0.91949,0.005175535,0.009086492,0.006045666,0.001790214,0.05297489,0.001308775,0.00003544814,0.004093004],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.008677581,"threshold_uncertainty_score":0.045892,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01402660249485692,"score_gpt":0.230289866264427,"score_spread":0.2162632637695701,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}